A031701, PI

A phase II study of Gemcitabine plus Cisplatin Chemotherapy in Patients with Muscle Invasive Bladder Cancer with Bladder Preservation for Those Patients in Whose tumors harbor deleterious DNA damage response (DDR) Gene Alterations